Technical Director Professor Sabine Flitsch will present Bio-Shape’s company profile and latest research at the IBioIC Annual Conference 25-26/01/2018.
Bio-Shape is a start-up company and has been in operation since 2016. It was founded by four academic scientists from Manchester and Liverpool Universities. Building on a combined expertise of >70 years of academic research, culminating in the commercialisation of biocatalysts and cutting edge synthetic and analytical tools to support biotechnology industries.
Bio-Shape specialises in applying mass spectrometry based methods to analyse large and complex biomolecules such as protein-based biopharmaceuticals to look at: structure, disorder, conformation, conformational change and aggregation with specific expertise in ion mobility mass spectrometry (IM-MS). Hydrogen deuterium exchange with mass spectrometry (HDX MS) is used for higher order structural studies, mapping binding sites and discovery and development of protein drugs.
Our research interests lie in the development of an IM-MS platform to unambiguously assign carbohydrate linkage details to polysaccharides from complex mixtures.[1-2] Development of our array-based mass spectrometry platform for glycan binding studies and characterisation of glycan binding proteins and glycoproteins is also a target.
A series of newly developed biocatalysts are available to purchase via Prozomix Limited www.prozomix.com and we continue to expand this collection of novel glycoenzymes. The collection includes enzymes for: sugar nucleotide syntheses, α-2,3 sialyltransferases, α-2,6 sialyltransferases, CMP-sialic acid synthases and exo-alpha-sialidases. Activities including: fucosyltransferases, galactosyltransferases, fucosidases and glycosyltransferases are expected by 2018.
 Gray C. J et al. BBA – General subjects, 2016. DOI: 10.1016/J.BBAGEN.2016.02.003
 Both, P et al. Nature Chemistry. 2014, 6(1); 65–74. DOI:10.1038/NCHEM.1817
 Gray, C. J et al. Analytical Chemistry, 2017, 89(8), 4444-4451. DOI: 10.1021/acs.analchem.6b04122